Skip to main content
. 2020 Oct 10;11(2):340–354. doi: 10.1016/j.apsb.2020.10.001

Figure 3.

Figure 3

Mainstream surface modifications for liposomes/lipid nanoparticles, as well as liposome–exosome hybrids in lncRNA drug delivery. Liposomes/lipid nanoparticles can be moderated by ligands, PEG, RGD, aptamers, linkers, or antibodies to improve delivery performance. In addition, liposome–exosome hybrids are new drug delivery agents that can be successfully applied in preclinical experiments. PEG, polyethylene glycol; RGD, arginine-glycine-aspartic acid peptide.